Clinical trial
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic…
NCT00039403 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039403 |
|---|---|
| Title | UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer |
| Official title | A Phase I Study Of UCN-01 In Combination With Gemcitabine In Unresectable Or Metastatic Pancreatic Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Drug, Other |
| Interventions | 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis |
| Enrollment | 30 |
| Start date | Apr 1, 2002 |
| Primary completion | May 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: